A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.
Por:
Rodríguez-Veiga R, Gil C, Sobas M, Torres-Miñana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Pérez-Encinas M, Algarra L, González-Campos J, Gómez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, García R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela Á, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodríguez-Macías G, Oleksiuk J, Lloret-Madrid P and Montesinos P
Ahead of Print:
13 nov 2025
Resumen:
Acute promyelocytic leukemia (APL) is a highly curable leukemia characterized by life-threatening coagulopathy leading to hemorrhagic and thrombo-ischemic events. We analyzed the incidence, outcomes and risk-factors of thromboischemic events in a large series of 1210 patients with newly diagnosed APL reported to the PETHEMA registry. Therapy consisted on ATRA and chemotherapy (AIDA-based). Median age of patients was 46 years (range 2-90 years). Fifty-eight patients (5%) did not start AIDA regimen as they were unfit for chemotherapy, or they died early before initiating ATRA. A total of 195 (16%) patients developed thrombo-ischemic events, the most frequent being superficial-vein and/or central catheter-related (6.9%) followed by central nervous system (2.2%), deep-vein thrombosis (2.1%), pulmonary embolism (2.1%), acute myocardial infarction (1.6%), or other locations (1.2%). Thromboischemic events mostly occurred at diagnosis and during induction (4.0%, and 9.3%, respectively). Patients developing life-threatening thrombo-ischemic events (i.e, excluding superficial and/or catheter-related) at diagnosis/induction had 31% early death rate. Prolonged aPTT, age >40 years, ECOG more than 1, platelets > 25 x 109/L, and absence of bleeding at presentation were independent risk factors for life-threatening thrombo-ischemic events. Using these variables (1 point each) we developed and validated the Thromb-On risk score, identifying a high-risk group (3 to 5 points). The Thromb-On risk score was validated in a cohort of 585 patients treated since 2017 with arsenic trioxide plus ATRA (<10x109 leukocytes) or AIDA (=10x109 leukocytes). This study could help to improve prevention and management of life-threatening thromboischemic events, through risk-adapted guidance, potentially leading to decrease early mortality in APL.
Filiaciones:
Rodríguez-Veiga R:
Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
Gil C:
Hematology Department, Hospital General Universitario Dr. Balmis, Alicante
Sobas M:
Hematology Department, Wroclaw Medical University
Torres-Miñana L:
Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
Botella C:
Hematology Department, Hospital General Universitario Dr. Balmis, Alicante
De la Serna J:
Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid
Bernal T:
Hematology Department, Hospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de investigación del Principado de Asturias (ISPA), Oviedo
Salamero O:
University Hospital Vall d'Hebron, and Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona
Otero C:
Hematology Department, Hospital Maciel, Montevideo
Navarro-Vicente I:
Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
De Miguel C:
Hematology Department, Hospital Puerta de Hierro, Madrid
Garrido A:
Hematology Department, Hospital de la Sant Creu i Sant Pau, Barcelona
:
Hematology Department, ICO-Hospital Universitari Germans Trias i Pujol, Institut de recerca Josep Carreras, Badalona
Bergua J:
Hematology Department, Hospital Universitario San Pedro de Alcántara, Cáceres
Pérez-Encinas M:
Hematology Department, Hospital Clínico Universitario, Santiago de Compostela
Algarra L:
Hematology Department, Hospital General Universitario de Albacete, Albacete
González-Campos J:
Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Sevilla
Gómez MDMC:
Hematology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria
Prates MV:
Hematology Department, Hospital Italiano de La Plata (HILP), La Plata
Benavente C:
Hematology Department, Hospital Clínico San Carlos, Madrid
Tormo M:
Hematology Department, Hospital Clínico Universitario-INCLIVA, Valencia
Cervera M:
Hematology Department, Hospital de Tarragona "Joan XXIII"(ICO-Tarragona), Tarragona
Fazio P:
Hematology Department, Hospital General San Martín, La Plata
Amutio ME:
Hematology Department, Hospital Universitario Cruces Barakaldo, Bizkaia
García R:
Hematology Department, Hospital General de Castellón, Castellón
Pomares H:
Hematology Department, Institut Catala d'Oncologia, Hospitalet del Llobregat
Vidriales B:
Hematology Department, Hospital Universitario de Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca
Serrano J:
Hematology Department, IMIBIC, Hematology, Hospital Universitario Reina Sofía, UCO, Córdoba
Amigo ML:
Hematology Department, Hospital Morales Meseguer, Murcia
Rubio V:
Hematology Department, Hospital General Jerez de la Frontera, Cadiz
Almela Á:
Hematology Department, Hospital Universitario de León, León
Barrios M:
Hematology Department, Hospital Carlos Haya (COMPLEJO HOSPITALARIO REGIONAL DE MÁLAGA), Málaga
Sossa-Melo CL:
Hematology Department, Fundación Oftalmológica de Santander-FOSCAL Facultad de Ciencias de la Salud, Universidad Autónoma de Bucaramanga-UNAB, Santander, Colombia
Paluszewska M:
Hematology Department, Medical University of Warsaw, Poland Hematology
Novo A:
Hematology Department, Hospital Son Espases, Palma de Mallorca
Gromek T:
Hematology Department, Medical University Lublin (SPSK1), Lublin
Rodríguez-Macías G:
Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid
Oleksiuk J:
Hematology Department, Medical University Bialystok, Bialystok
Lloret-Madrid P:
Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
Montesinos P:
Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
|